Stephan Strass

Stephan advises innovative start-ups, institutional and strategic investors and other companies on acquisitions, financing rounds, joint ventures and exit transactions with a focus on highly regulated industries such as life sciences, biotech and leisure & entertainment. He further specializes in commercial transactions in the life science and biotech sector, including university spin-offs, strategic collaborations, patent and technology license agreements and IP purchase transactions.

He has co-authored commentaries on the EU Merger Act and the Investment Fund Act, and is the author of many academic publications.

Advising Sportradar on its initial public offering on NASDAQ

Advising AC Immune on the acquisition of a vaccine candidate against Parkinson's disease (Affiris)

Advising the shareholders of Allcyte on the sale to Exscientia

Advising the seller consortium, including Farallon, Global Health Investment Fund, Wellington Partners and Ventech on the sale of Themis to Merck Sharp Dohme

Advising numerous start-ups and other companies in the life sciences sector on university spin-offs and technology transactions